News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
118,209 Results
Type
Article (8829)
Company Profile (41)
Press Release (109339)
Section
Business (32299)
Career Advice (153)
Deals (4749)
Drug Delivery (33)
Drug Development (19506)
Employer Resources (13)
FDA (4064)
Job Trends (2592)
News (61413)
Policy (7214)
Tag
2024 BioForest Digital (1)
2024 Bio NC Digital (2)
2024 Biotech Bay Standard (2)
2024 Biotech Beach Digital (3)
2024 Biotech Beach Standard (3)
2024 Genetown Standard (2)
2024 Lone Star Bio Digital (1)
2024 Pharm Country Digital (1)
2025 Lone Star Bio Digital (1)
2026 Pharm Country Premier (1)
Academia (540)
Accelerated approval (1)
Adcomms (9)
Allergies (31)
Alliances (10335)
ALS (13)
Alzheimer's disease (271)
Antibody-drug conjugate (ADC) (39)
Approvals (4074)
Artificial intelligence (45)
Autoimmune disease (8)
Automation (3)
Bankruptcy (25)
Best Places to Work (2247)
BIOSECURE Act (16)
Biosimilars (78)
Biotechnology (27)
Bladder cancer (21)
Brain cancer (7)
Breast cancer (55)
Cancer (526)
Cardiovascular disease (21)
Career advice (132)
Career pathing (4)
CAR-T (35)
Cell therapy (118)
Cervical cancer (3)
Clinical research (16055)
Collaboration (200)
Compensation (49)
Complete response letters (11)
COVID-19 (576)
CRISPR (9)
C-suite (55)
Cystic fibrosis (14)
Data (534)
Decentralized trials (1)
Denatured (2)
Depression (5)
Diabetes (39)
Diagnostics (654)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (6)
Drug discovery (29)
Drug pricing (22)
Drug shortages (1)
Duchenne muscular dystrophy (38)
Earnings (11239)
Editorial (6)
Employer branding (3)
Employer resources (12)
Events (15252)
Executive appointments (122)
FDA (4459)
Featured Employer (10)
Frontotemporal dementia (1)
Funding (156)
Gene editing (30)
Generative AI (5)
Gene therapy (92)
GLP-1 (132)
Government (1406)
Grass and pollen (1)
Guidances (14)
Healthcare (2915)
Huntington's disease (2)
IgA nephropathy (2)
Immunology and inflammation (39)
Indications (8)
Infectious disease (610)
Inflammatory bowel disease (49)
Inflation Reduction Act (4)
Influenza (15)
Intellectual property (16)
Interviews (20)
IPO (2145)
IRA (13)
Job creations (437)
Job search strategy (122)
Kidney cancer (3)
Labor market (2)
Layoffs (59)
Leadership (1)
Legal (746)
Liver cancer (17)
Lung cancer (75)
Lymphoma (45)
Machine learning (1)
Management (3)
Manufacturing (104)
MASH (12)
Medical device (1909)
Medtech (1910)
Mergers & acquisitions (2698)
Metabolic disorders (104)
Multiple sclerosis (16)
NASH (2)
Neurodegenerative disease (20)
Neuropsychiatric disorders (1)
Neuroscience (347)
NextGen: Class of 2025 (877)
Non-profit (481)
Northern California (570)
Now hiring (11)
Obesity (42)
Opinion (51)
Ovarian cancer (22)
Pain (15)
Pancreatic cancer (13)
Parkinson's disease (9)
Partnered (3)
Patents (33)
Patient recruitment (27)
Peanut (21)
People (9225)
Pharmaceutical (12)
Pharmacy benefit managers (2)
Phase I (5095)
Phase II (6716)
Phase III (5852)
Pipeline (326)
Podcasts (6)
Policy (39)
Postmarket research (505)
Preclinical (1973)
Press Release (66)
Prostate cancer (24)
Psychedelics (5)
Radiopharmaceuticals (54)
Rare diseases (96)
Real estate (1009)
Recruiting (4)
Regulatory (5774)
Reports (12)
Research institute (542)
Resumes & cover letters (14)
RNA editing (1)
RSV (10)
Schizophrenia (12)
Series A (35)
Series B (14)
Service/supplier (3)
Sickle cell disease (20)
Southern California (539)
Special edition (3)
Spinal muscular atrophy (23)
Sponsored (9)
Startups (671)
State (1)
Stomach cancer (3)
Supply chain (12)
The Weekly (4)
United States (4702)
Vaccines (194)
Venture capitalists (4)
Webinars (1)
Weight loss (21)
Women's health (5)
Date
Today (32)
Last 7 days (188)
Last 30 days (653)
Last 365 days (7616)
2025 (1895)
2024 (7857)
2023 (8472)
2022 (11359)
2021 (11718)
2020 (10141)
2019 (7441)
2018 (5802)
2017 (6446)
2016 (5876)
2015 (6741)
2014 (4774)
2013 (3767)
2012 (3889)
2011 (4149)
2010 (3394)
Location
Africa (112)
Alabama (12)
Alaska (1)
Arizona (18)
Arkansas (3)
Asia (9191)
Australia (1137)
California (1314)
Canada (266)
China (182)
Colorado (38)
Connecticut (35)
Delaware (41)
Europe (17095)
Florida (193)
Georgia (20)
Idaho (13)
Illinois (74)
India (11)
Indiana (50)
Iowa (1)
Japan (35)
Kansas (8)
Kentucky (10)
Louisiana (2)
Maine (5)
Maryland (324)
Massachusetts (886)
Michigan (26)
Minnesota (51)
Mississippi (1)
Missouri (15)
Montana (5)
Nebraska (1)
Nevada (4)
New Hampshire (3)
New Jersey (491)
New Mexico (5)
New York (368)
North Carolina (213)
North Dakota (7)
Northern California (570)
Ohio (50)
Oklahoma (7)
Oregon (8)
Pennsylvania (211)
Puerto Rico (2)
Rhode Island (6)
South America (163)
South Carolina (2)
Southern California (539)
Tennessee (6)
Texas (152)
Utah (29)
Virginia (26)
Washington D.C. (6)
Washington State (99)
Wisconsin (8)
118,209 Results for "bone biologics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Genetown
First Two Patients Treated in Pilot Clinical Study with Bone Biologics’ NB1 Bone Graft Device in Spine Fusion
Bone Biologics Corporation announces that the first two patients have been treated in the multicenter, prospective, randomized pilot clinical study of the Company’s NB1 bone graft device.
June 20, 2024
·
5 min read
Genetown
Bone Biologics Reports Progress With NB1 Clinical Program
Bone Biologics Corporation, a developer of orthobiologic products for spine fusion markets, reports progress with advancing its product candidate NB1 into human clinical testing for spinal fusion.
March 1, 2024
·
3 min read
Deals
Bone Biologics Announces Pricing of $2.0 Million Public Offering
Bone Biologics Corporation today announced the pricing of its public offering of an aggregate of 781,251 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 781,251 shares of common stock.
March 4, 2024
·
4 min read
Genetown
Bone Biologics Announces Closing of $2.0 Million Public Offering
Bone Biologics Corporation announced the closing of its previously announced public offering of an aggregate of 781,251 shares of its common stock and warrants to purchase up to 781,251 shares of common stock, at a public offering price of $2.56 per share and accompanying warrant.
March 6, 2024
·
3 min read
Obesity
Amgen Suffers Surprise Blow as New Bone Density Safety Concerns for MariTide Surface
Cantor Fitzgerald analyst Olivia Brayer found supplementary bone mineral density data for Amgen’s obesity candidate MariTide that could point to a potentially greater fracture risk than previously revealed, but some other analysts view the findings as a nonissue.
November 13, 2024
·
2 min read
·
Tristan Manalac
Business
Bone Biologics Appoints Healthcare Finance Veteran Robert E. Gagnon to Board of Directors
Bone Biologics Corporation today announced that effective immediately Robert E. Gagnon has been named to the Company’s board of directors.
January 11, 2024
·
3 min read
Genetown
Bone Biologics Provides Scientific Update on NB1 Bone Graft Device
Bone Biologics Corporation (NASDAQ: BBLG) , a developer of orthobiologic products for spine fusion markets, provides an update on its clinical development initiatives with its NB1 bone graft device.
September 26, 2023
·
6 min read
Deals
Bone Biologics Regains Compliance with Nasdaq Continued Listing Requirements
Bone Biologics Corporation today announced that it has received notice from The NASDAQ Stock Market LLC (Nasdaq) informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market.
January 10, 2024
·
1 min read
Genetown
Bone Biologics Announces 1-for-8 Reverse Stock Split
Bone Biologics Corporation, a developer of orthobiologic products for spine fusion markets, announced a planned reverse stock split of its shares of common stock at a ratio of 1-for-8.
December 18, 2023
·
3 min read
Press Releases
Orthofix Receives 510(k) Clearance and CE Mark for TrueLok Elevate Transverse Bone Transport System
March 19, 2025
·
5 min read
1 of 11,821
Next
